Do analysts prefer CYCN or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, CYCN or ZYBT?

Cyclerion Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclerion Therapeutics $2.07M 7.89 -$3.53M -$1.66 N/A Zhengye Biotechnology $116.36M 0.53 -$9.98M N/A N/A

Do analysts prefer SPRO or CYCN?

Spero Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 387.80%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LONA or CYCN?

Athira Pharma presently has a consensus price target of $17.33, suggesting a potential upside of 433.33%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TLPH or CYCN?

Talphera currently has a consensus price target of $3.00, indicating a potential upside of 154.24%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts clearly believe Talphera is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor TLPH or CYCN?

In the previous week, Talphera had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Talphera and 1 mentions for Cyclerion Therapeutics. Talphera's average media sentiment score of 0.91 beat Cyclerion Therapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Talphera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cyclerion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate HRTX or CYCN?

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 578.66%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Heron Therapeutics is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer HRTX or CYCN?

In the previous week, Heron Therapeutics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Cyclerion Therapeutics. Heron Therapeutics' average media sentiment score of 0.65 beat Cyclerion Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cyclerion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cyclerion Therapeutics (CYCN) Competitors

$3.49 +0.13 (+3.87%)

Closing price 09/8/2026

Extended Trading

$3.49 0.00 (0.00%)

As of 09/8/2026 07:42 PM Eastern

Compare

CYCN vs. ZYBT, SPRO, LONA, TLPH, and HRTX

Should you buy Cyclerion Therapeutics stock or one of its competitors? Cyclerion Therapeutics's main competitors and comparable companies include Zhengye Biotechnology (ZYBT), Spero Therapeutics (SPRO), Athira Pharma (LONA), Talphera (TLPH), and Heron Therapeutics (HRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Cyclerion Therapeutics (NASDAQ:CYCN) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclerion Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A
Zhengye Biotechnology	$116.36M	0.53	-$9.98M	N/A	N/A

Zhengye Biotechnology has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Zhengye Biotechnology's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%
Zhengye Biotechnology	N/A	N/A	N/A

Cyclerion Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.56, suggesting that its share price is 356% less volatile than the broader market.

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Cyclerion Therapeutics and Cyclerion Therapeutics both had 1 articles in the media. Zhengye Biotechnology's average media sentiment score of 1.82 beat Cyclerion Therapeutics' score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Cyclerion Therapeutics	Neutral
Zhengye Biotechnology	Very Positive

Summary

Cyclerion Therapeutics and Zhengye Biotechnology tied by winning 5 of the 10 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Spero Therapeutics has higher revenue and earnings than Cyclerion Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.07	$8.57M	$0.11	11.18
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Spero Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 387.80%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Spero Therapeutics and Spero Therapeutics both had 1 articles in the media. Spero Therapeutics' average media sentiment score of 1.82 beat Cyclerion Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Very Positive
Cyclerion Therapeutics	Neutral

Spero Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Cyclerion Therapeutics' net margin of -170.11%. Spero Therapeutics' return on equity of 16.17% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Summary

Spero Therapeutics beats Cyclerion Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Cyclerion Therapeutics has higher revenue and earnings than Athira Pharma. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

Athira Pharma has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Athira Pharma has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market.

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Athira Pharma presently has a consensus price target of $17.33, suggesting a potential upside of 433.33%. Given Athira Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Athira Pharma is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Athira Pharma had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Athira Pharma and 1 mentions for Cyclerion Therapeutics. Athira Pharma's average media sentiment score of 1.41 beat Cyclerion Therapeutics' score of 0.00 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Positive
Cyclerion Therapeutics	Neutral

Summary

Athira Pharma beats Cyclerion Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Talphera?

Talphera (NASDAQ:TLPH) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Cyclerion Therapeutics has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Cyclerion Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$1K	61,249.08	-$14.29M	-$0.27	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

Talphera currently has a consensus price target of $3.00, indicating a potential upside of 154.24%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts clearly believe Talphera is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

37.7% of Talphera shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Talphera has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Talphera's return on equity of -87.28% beat Cyclerion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

In the previous week, Talphera had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Talphera and 1 mentions for Cyclerion Therapeutics. Talphera's average media sentiment score of 0.91 beat Cyclerion Therapeutics' score of 0.00 indicating that Talphera is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cyclerion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Talphera has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Summary

Talphera beats Cyclerion Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

In the previous week, Heron Therapeutics had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Cyclerion Therapeutics. Heron Therapeutics' average media sentiment score of 0.65 beat Cyclerion Therapeutics' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cyclerion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Heron Therapeutics presently has a consensus target price of $2.00, suggesting a potential upside of 578.66%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Heron Therapeutics is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclerion Therapeutics has lower revenue, but higher earnings than Heron Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.36	-$20.19M	-$0.19	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

Heron Therapeutics has a net margin of -22.52% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Heron Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Summary

Heron Therapeutics beats Cyclerion Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYCN vs. The Competition

Export

Metric	Cyclerion Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$16.33M	$12.52B	$7.26B	$13.16B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-2.10	792.35	274.71	25.77
Price / Sales	7.89	1,000.51	681.32	110.43
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.51	10.62	10.46	6.30
Net Income	-$3.53M	$2.81B	$3.49B	$359.77M
7 Day Performance	N/A	-1.02%	-1.25%	-0.16%
1 Month Performance	-87.54%	-2.93%	-4.51%	-4.06%
1 Year Performance	-81.74%	2.57%	16.42%	6.10%

Cyclerion Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYCN Cyclerion Therapeutics	0.6603 of 5 stars	$3.49 +3.9%	N/A	-84.7%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
ZYBT Zhengye Biotechnology	0.9713 of 5 stars	$1.37 -0.4%	N/A	-73.6%	$65.12M	$116.36M	N/A	278	Positive News
SPRO Spero Therapeutics	4.0771 of 5 stars	$1.12 -1.3%	$6.00 +438.1%	-36.5%	$64.94M	$66.80M	10.14	150	Positive News
LONA Athira Pharma	3.9192 of 5 stars	$6.81 -5.9%	$17.33 +154.5%	N/A	$64.93M	N/A	N/A	40	Positive News Short Interest Decrease Gap Up
TLPH Talphera	2.2468 of 5 stars	$1.19 flat	$3.00 +152.1%	+26.7%	$61.77M	$1K	N/A	19

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYCN) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclerion Therapeutics (CYCN) Competitors

CYCN vs. ZYBT, SPRO, LONA, TLPH, and HRTX

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Summary

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Summary

How does Cyclerion Therapeutics compare to Athira Pharma?

Summary

How does Cyclerion Therapeutics compare to Talphera?

Summary

How does Cyclerion Therapeutics compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN vs. The Competition

Cyclerion Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclerion Therapeutics (CYCN) Competitors

CYCN vs. ZYBT, SPRO, LONA, TLPH, and HRTX

How does Cyclerion Therapeutics compare to Zhengye Biotechnology?

Do analysts prefer CYCN or ZYBT?

Which has better valuation & earnings, CYCN or ZYBT?

Is CYCN or ZYBT more profitable?

Which has more risk and volatility, CYCN or ZYBT?

Do institutionals and insiders believe in CYCN or ZYBT?

Does the media favor CYCN or ZYBT?

Summary

How does Cyclerion Therapeutics compare to Spero Therapeutics?

Which has stronger earnings and valuation, SPRO or CYCN?

Do institutionals & insiders believe in SPRO or CYCN?

Do analysts prefer SPRO or CYCN?

Does the media refer more to SPRO or CYCN?

Which has more volatility & risk, SPRO or CYCN?

Is SPRO or CYCN more profitable?

Summary

How does Cyclerion Therapeutics compare to Athira Pharma?

Which has higher earnings and valuation, LONA or CYCN?

Is LONA or CYCN more profitable?

Which has more volatility and risk, LONA or CYCN?

Do insiders and institutionals have more ownership in LONA or CYCN?

Do analysts rate LONA or CYCN?

Does the media refer more to LONA or CYCN?

Summary

How does Cyclerion Therapeutics compare to Talphera?

Which has stronger earnings and valuation, TLPH or CYCN?

Do analysts prefer TLPH or CYCN?

Do insiders & institutionals believe in TLPH or CYCN?

Is TLPH or CYCN more profitable?

Does the media favor TLPH or CYCN?

Which has more risk and volatility, TLPH or CYCN?

Summary

How does Cyclerion Therapeutics compare to Heron Therapeutics?

Does the media prefer HRTX or CYCN?

Do institutionals and insiders hold more shares of HRTX or CYCN?

Do analysts rate HRTX or CYCN?

Which has higher valuation & earnings, HRTX or CYCN?

Is HRTX or CYCN more profitable?

Which has more risk and volatility, HRTX or CYCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYCN vs. The Competition

Cyclerion Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools